FeesSafety
Pluang+

Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Company Fundamentals
19 Nov 2026, 05:00 WIB
Tony Dante
View Source
Bullish
Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Alpha Tau Medical is set to report earnings on November 19, 2026, with expected losses of $0.15 per share and revenue of $125,000. The company announced positive clinical trial results from its U.S. REGAIN trial for Alpha DaRT therapy in glioblastoma patients, showing objective responses in all six assessed patients, including five complete responses. These promising results, alongside potential FDA approval in 2027 for another treatment, have supported a Buy rating from Seeking Alpha. However, the small trial size means efficacy is not yet fully proven, though safety and feasibility are confirmed.

Alpha Tau Medical's earnings and clinical trial results provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 19, 2026 05:11 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 51 rose and 98 fell today. Notable movers include SYRE at USD 101.41 (+8.10%), IBRX at USD 6.75 (+7.83%), and OSCR at USD 27.61 (-7.47%).

More News

Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia's stock dropped 2.9% to $150.96 after initially rising on strong quarterly results and a raised revenue forecast for fiscal 2028, projecting 75% annual growth. However, investor concerns about leadership uncertainty, including calls for former...

Neutral
1 hour ago
B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods increased its full-year net sales and adjusted EBITDA guidance following a 5% volume-driven sales growth in Q3 2026. The company is expanding beyond traditional retail into food service, clubs, and private labels to utilize factory capacity...

Company Fundamentals
Bullish
1 hour ago
CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave's stock fell 4.13% despite strong AI demand and Nvidia's solid earnings, as investors focus on the company's heavy debt and financing challenges. The company reported 168% revenue growth and raised its 2026 revenue forecast to $13-$13.3 bil...

Bearish
1 hour ago
Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group reported a 5.5% net sales increase in fiscal Q1 2027, driven by growth in independent restaurant orders and expanding gross profit margins. The company aims to achieve $125 million in annual procurement savings by fiscal 2028 t...

Company Fundamentals
Bullish
1 hour ago
US Foods reports 10% EBITDA growth, acquires Prime Line, and boosts AI-driven sales efficiency.

US Foods reports 10% EBITDA growth, acquires Prime Line, and boosts AI-driven sales efficiency.

US Foods reported a 10% increase in adjusted EBITDA to $555 million in Q3 2026, driven by profit margin expansion and market share gains. The company acquired specialty distributor Prime Line to broaden its specialty Italian product offerings and enh...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App